Please login to the form below

Not currently logged in
Email:
Password:

NovaMedica appoints Fabrice Egros chief operating officer

Joint Russian-US venture has also appointed Mary Anderson to US role

Recently-launched pharmaceutical company NovaMedica has appointed Fabrice Egros as its chief operating officer.

The company was formed in 2011 as part of a $760m collaboration between the Russian technology investment fund Rusnano and US healthcare venture fund Domain Associates.

The partnership involves joint investing in advanced medical technologies and late stage innovative drugs for their development, manufacture and commercialisation, and will see the firm create a GMP production facility in Russia.

Egros has more than 20 years of pharma experience, most recently as chief operating officer at Xanodyne and before that as senior vice president of corporate business development and strategy at UCB.

He has also held various roles at Parke-Davis/Warner Lambert in Germany and the US and Sanofi in Japan and the US.

“I see my top priority in the creation of a great team of globally experienced life sciences industry talents from R&D, CMC, regulatory, business development, marketing and sales, to create the next generation life science company in Russia,” said Egros.

Headquartered in Moscow, Russia, NovaMedica has also recently set up US offices in Princeton, New Jersey, appointing Mary Anderson to lead its business development efforts.

She has over 22 years of international licensing and business development experience and comes to the company from the oncology division of Merck KGaA, where she spent five years as head of licensing and business development.

Prior to Merck KgaA, Anderson held various business development positions including serving ten years at Bayer.

26th November 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics